OPEN Foundation

Role of psilocybin in the treatment of depression

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Abstract

Psilocybin is a naturally occurring alkaloid, pharmacologically similar to the classic hallucinogen lysergic acid diethylamide (LSD). Although primarily used as a recreational drug or an entheogen in particular cultural settings, recent population based studies have shown that it does not lead to serious physical or mental health problems or dependent use. In view of recent work demonstrating psilocybin’s potential to increase subjective sense of wellbeing and because of its novel mechanism of 5-HT2A serotonin receptor agonism, it is being explored for possible therapeutic utility in mood and anxiety disorders.

Mahapatra, A., & Gupta, R. (2016). Role of psilocybin in the treatment of depression. Therapeutic Advances in Psychopharmacology, 2045125316676092.
Link to full text

OPEN Foundation

Attend the Interdisciplinary Conference on Psychedelic Research

ICPR features world-leading experts from many academic disciplines, including psychiatry, psychology, neuroscience, anthropology, ethnobotany, and philosophy who come together to give a scientific conference for academics, therapists, researchers, clinicians, policymakers, and members of the public. Get your ICPR 2022 ticket here and use the code OPENBLOG100 at checkout for a €100 discount on all tickets.

More Info

INTERESTED IN PSYCHEDELIC RESEARCH AND THERAPIES?

Subscribe to our new OPEN-Minded newsletter to stay in the loop, hear about our events, and become a part of a community dedicated to advancing psychedelics.

By clicking subscribe, I confirm to receive emails from the OPEN Foundation and agree with its privacy policy.